Gerard F Curley1, Nadine Shehata, C David Mazer, Gregory M T Hare, Jan O Friedrich. 1. 1Departments of Anesthesia and Critical Care, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 2Departments of Medicine and Laboratory Medicine and Pathobiology (Mount Sinai Hospital), Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 3Department of Anesthesia, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 4Departments of Critical Care and Medicine, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Abstract
OBJECTIVE: Restrictive red cell transfusion is recommended to minimize risk associated with exposure to allogeneic blood. However, perioperative anemia is an independent risk factor for adverse outcomes after cardiovascular surgery. The purpose of this systematic review and meta-analysis is to determine whether perioperative restrictive transfusion thresholds are associated with inferior clinical outcomes in randomized trials of cardiovascular surgery patients. DATA SOURCES: The Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE from inception to October 2013; reference lists of published guidelines, reviews, and associated articles, as well as conference proceedings. No language restrictions were applied. STUDY SELECTION: We included controlled trials in which adult patients undergoing cardiac or vascular surgery were randomized to different transfusion thresholds, described as a hemoglobin or hematocrit level below which RBCs were transfused. DATA EXTRACTION: Two authors independently extracted data from included trials. We pooled risk ratios of dichotomous outcomes and mean differences of continuous outcomes across trials using random-effects models. DATA SYNTHESIS: Seven studies (enrolling 1,262 participants) met inclusion criteria with restrictive and liberal transfusion thresholds most commonly differing by a hemoglobin of 1 g/dL or hematocrit of 6-7%, resulting in decreased transfusions by 0.71 units of RBCs (95% CI, 0.31-1.09, p = 0.0002) without an associated change in adverse events: mortality (risk ratio, 1.12; 95% CI, 0.65-1.95; p = 0.60), myocardial infarction (risk ratio, 0.94; 95% CI, 0.30-2.99; p = 0.92), stroke (risk ratio, 1.15; 95% CI, 0.57-2.32; p = 0.70), acute renal failure (risk ratio, 0.98; 95% CI, 0.64-1.49; p = 0.91), infections (risk ratio, 1.23; 95% CI, 0.85-1.78; p = 0.27), or length of stay. There was no between-trial heterogeneity for any pooled analysis. Including four pediatric trials (456 participants) and 10 trials utilizing only intraoperative acute normovolemic hemodilution (872 participants) did not substantially change the results except that unlike the transfusion threshold trials, the hemodilution trials did not reduce the proportion of patients transfused (interaction p = 0.01). CONCLUSIONS: Further randomized controlled trials are necessary to determine the optimal transfusion strategy for patients undergoing cardiovascular surgery.
OBJECTIVE: Restrictive red cell transfusion is recommended to minimize risk associated with exposure to allogeneic blood. However, perioperative anemia is an independent risk factor for adverse outcomes after cardiovascular surgery. The purpose of this systematic review and meta-analysis is to determine whether perioperative restrictive transfusion thresholds are associated with inferior clinical outcomes in randomized trials of cardiovascular surgery patients. DATA SOURCES: The Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE from inception to October 2013; reference lists of published guidelines, reviews, and associated articles, as well as conference proceedings. No language restrictions were applied. STUDY SELECTION: We included controlled trials in which adult patients undergoing cardiac or vascular surgery were randomized to different transfusion thresholds, described as a hemoglobin or hematocrit level below which RBCs were transfused. DATA EXTRACTION: Two authors independently extracted data from included trials. We pooled risk ratios of dichotomous outcomes and mean differences of continuous outcomes across trials using random-effects models. DATA SYNTHESIS: Seven studies (enrolling 1,262 participants) met inclusion criteria with restrictive and liberal transfusion thresholds most commonly differing by a hemoglobin of 1 g/dL or hematocrit of 6-7%, resulting in decreased transfusions by 0.71 units of RBCs (95% CI, 0.31-1.09, p = 0.0002) without an associated change in adverse events: mortality (risk ratio, 1.12; 95% CI, 0.65-1.95; p = 0.60), myocardial infarction (risk ratio, 0.94; 95% CI, 0.30-2.99; p = 0.92), stroke (risk ratio, 1.15; 95% CI, 0.57-2.32; p = 0.70), acute renal failure (risk ratio, 0.98; 95% CI, 0.64-1.49; p = 0.91), infections (risk ratio, 1.23; 95% CI, 0.85-1.78; p = 0.27), or length of stay. There was no between-trial heterogeneity for any pooled analysis. Including four pediatric trials (456 participants) and 10 trials utilizing only intraoperative acute normovolemic hemodilution (872 participants) did not substantially change the results except that unlike the transfusion threshold trials, the hemodilution trials did not reduce the proportion of patients transfused (interaction p = 0.01). CONCLUSIONS: Further randomized controlled trials are necessary to determine the optimal transfusion strategy for patients undergoing cardiovascular surgery.
Authors: Amit X Garg; Neal Badner; Sean M Bagshaw; Meaghan S Cuerden; Dean A Fergusson; Alexander J Gregory; Judith Hall; Gregory M T Hare; Boris Khanykin; Shay McGuinness; Chirag R Parikh; Pavel S Roshanov; Nadine Shehata; Jessica M Sontrop; Summer Syed; George I Tagarakis; Kevin E Thorpe; Subodh Verma; Ron Wald; Richard P Whitlock; C David Mazer Journal: J Am Soc Nephrol Date: 2019-06-20 Impact factor: 10.121
Authors: Nadine Shehata; Nikhil Mistry; Bruno R da Costa; Tiago V Pereira; Richard Whitlock; Gerard F Curley; David A Scott; Gregory M T Hare; Peter Jüni; C David Mazer Journal: Eur Heart J Date: 2019-04-01 Impact factor: 29.983
Authors: Joshua Goldberg; Theron A Paugh; Timothy A Dickinson; John Fuller; Gaetano Paone; Patty F Theurer; Kenneth G Shann; Thoralf M Sundt; Richard L Prager; Donald S Likosky Journal: Ann Thorac Surg Date: 2015-07-21 Impact factor: 4.330
Authors: Gaya Spolverato; Fabio Bagante; Matthew Weiss; Jin He; Christopher L Wolfgang; Fabian Johnston; Martin A Makary; Will Yang; Steven M Frank; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2016-09-30 Impact factor: 3.452
Authors: Dylan R Addis; Blake A Moore; Chandrika R Garner; Rohesh J Fernando; Sung M Kim; Gregory B Russell Journal: J Cardiothorac Vasc Anesth Date: 2019-11-01 Impact factor: 2.628